I am proud to offer this opportunity. I would like to start my presentation. IPS technology can generate cancer cells generated from patients. These cancer cells can transform into cardiomyocytes. Cardiomyocytes can generate changes in cancer cells. Web form changes, athmia changes, and cardiomyocyte changes can occur. By exploiting this change, new drugs can be detected through frequent screening. It is also possible to check the differences in drug response between each cardiomyocyte. But each problem will be solved. First, cancer cells generated by cardiomyocytes are immature. In fact, cancer cells generated by cardiomyocytes are similar to fatal station cardiomyocytes. On the contrary, this cardiomyocyte has heterogenity. In other words, it is a combination of Bendricure, Eatorial, and Nozal cells. You can see the difference in cancer cells generated by cardiomyocytes and the response to drugs. First, cardiomyocytes must be generated efficiently. The generated cardiomyocytes need to cleanse the cancer cells generated by the generated cardiomyocytes. First, we'll talk about using new RNA technology to cleanse. Many cell types have specific cell designations. For example, there are cells such as CD3 and CD4 link sites. This cell can be cleaned using specific cell designations. However, there is no specific cell designation for the various cells of cardiomyocytes. So I thought of the necessary approach. In collaboration with Hero, we used Synthetech RNA technology by experts in RNA technology. This is called microRNA switch technology. We generated synthetic RNA and combined the target microRNA complementary sequence with the reporter protein coding sequence. This RNA complementary sequence is generated from the reporter protein when the reporter protein does not use the target microRNA. Conversely, when the reporter protein does not use the target microRNA, this RNA complementary sequence is generated from the reporter protein. Due to differences in the expression of reporter proteins, The target microRNA complementary sequence is generated from the target microRNA complementary sequence. Using this system, this microRNA complementary sequence can be used to differentiate cardion myocytes from non-cardion myocytes to specific cardion myocytes. I am trying to validate my target microRNA complementary sequence. Using this transcriptomic analysis, we found that We use 14 types of microRNA. For this microRNA switch, this microRNA switch is coming out of the preptent stem cell. At the same time, RNA is called GFP. When this RNA is introduced into non-target cells, GFP and BFP expression is discordant. However, when this RNA is introduced into the target cell, The wording of BFP has changed. Thus, the expression of GFP and BFP changed. When these 14 RNAs were introduced into non-target cells using R499A against the microRNA switch, GFP and BFP expression changed. Ermine staining and flow cytometric analysis were performed. The results of selecting cardiomyocytes were confirmed. The percentage of trapolinti-positive cells was over 95%, which was higher than the conventional exploration method. Next, you must use cell exploration to find the cardeomyocytes. For this purpose, from florescant protein Moved to Elminestive Cell. When this RNA is input into cardiomyocytes, erminestive cells are expressed, and these cells transition into erminestive cells. Conversely, when this RNA is input into cardiomyocytes, erminestive cells are expressed, and this cell transitions into erminestive cells. Finally, Trapolinti positive cells must be removed. Trapolinti positive cells must be removed. The migration efficiency of Trapolinti positive cells is approximately 80%. Trapolinti positive cells must be removed. For this, it is necessary to remove the erminestive cells at the same time. For this, it is necessary to remove Traporinti positive cells. We have confirmed that cardion myocytes transplanted into the heart can survive for 3 months after transplantation.Cardion myocytes transplanted into the NMRG mask can survive. This is the test result of cardion myocytes transplanted into the heart. As you can see, many of the cells in the cardion myocytes are good for human fat. This is the test result for Corexin 43. Look at the expression of Corexin 43. Corexin 43 is an important test result for gap junction formation. Displayed in the graph and interface of the host cardion myosite. Recently, we performed VMIR examination of ventrigula cardion myocytes. we VMIR cardion myocytes were examined using Micro Annes Switch technology. MIL-C2V ventrigra cardion myocytes are highly represented in VMIR cardion myocytes. We also used Q-RT-PCR to express MIL-C2V and IRX-4 ventrigracardion myocytes. Compatible with VMIR Cardion Myosite. Recently, we combined Macro Annes Switch technology with Max Sorting. In high-throughput screening and religation medicine, many cardion myocytes must be prepared. It's about millions of cardion myocytes. For this, Contains a specific domain of CD4 as a reporter protein. When this probe enters the cardion myocyte, the expression of CD4 is replaced. Also, when this probe enters the cardion myocyte, the expression of CD4 is replaced. In this way, cardion myocytes can be cleaned using the Max Sorting System. Also, Puromycin-resistant GNRNA was removed after max sorting and confirmed in two independent i-Pace cell lines. This combination system uses the Max Sorting System and the Micraness Switch to efficiently clean cardion myocytes. The percentage of trponity positive cellulosis is 99% to 98%. This is the percentage of trponity positive cellulosis before and after cleaning the cardion myocytes. The rate of trponity positive cellulosis before and after efficient cleaning of cardion myocytes We also conducted an RNA test. The percentage of truponity positive cellulesis before and after efficiently cleaning cardion myocytes is the percentage of truponity positive cellulesis before and after efficiently cleaning cardion myocytes. As a result, we conducted an RNA test and

IPS technology

cancer cells

cardiomyocytes

RNA technology

drug development